Department of Nuclear Medicine, Sheba Medical Center, Derech Sheba 2, 52621, Ramat Gan, Tel-Hashomer, Israel.
Sackler Faculty of Medicine, Tel-Aviv University, 6997801, Tel-Aviv, Israel.
Sci Rep. 2021 Mar 15;11(1):5912. doi: 10.1038/s41598-021-85300-8.
While penile metastases are rare, PET/CT has facilitated their detection. We aimed to describe penile secondary lesions (PSL) identified by PET/CT. We reviewed 18F-FDG and Ga68-PSMA PET/CT records performed in a single center during May 2012-March 2020, for PSL. Of 16,774 18F-FDG and 1,963 Ga68-PSMA-PET scans, PSL were found in 24(0.13%) men with a mean age of 74. PSMA detected PSL in 12 with prostate cancer; FDG identified PSL in 4 with lymphoma, 3 with colorectal cancer, 2 with lung cancer, and one each with bladder cancer, pelvic sarcoma, and leukemia. Mean SUVmax of PSL was 7.9 ± 4.2 with focal uptake in 13(54%). Mean lesion size was 16.5 ± 6.8 mm; 8 at the penile root, 4 along the shaft, and 1 at the glans. CT detected loss of the penile texture in 15(63%). PSL were observed only during relapse or follow-up of disseminated disease. Among those with prostate cancer, PSA varied widely. Fifteen (62.5%) died, at a mean 13.3 ± 15.9 months following PSL demonstration, nine had non-prostate malignancies. PET/CT identified and characterized PSL in a fraction of cancer patients, most commonly those with prostate cancer. PSL universally surfaced in advanced disease, and signaled high mortality, especially in non-prostate cancers.
尽管阴茎转移瘤很少见,但 PET/CT 已有助于其检测。我们旨在描述 PET/CT 发现的阴茎继发性病变(PSL)。我们回顾了 2012 年 5 月至 2020 年 3 月在一家中心进行的 18F-FDG 和 Ga68-PSMA PET/CT 记录,以寻找 PSL。在 16774 次 18F-FDG 和 1963 次 Ga68-PSMA-PET 扫描中,24 名男性(0.13%)发现了 PSL,平均年龄为 74 岁。PSMA 在 12 名前列腺癌患者中检测到 PSL;FDG 在 4 名淋巴瘤患者、3 名结直肠癌患者、2 名肺癌患者和 1 名膀胱癌患者、1 名骨盆肉瘤患者和 1 名白血病患者中识别出 PSL。PSL 的平均 SUVmax 为 7.9±4.2,13 例(54%)呈局灶性摄取。平均病变大小为 16.5±6.8mm;8 例位于阴茎根部,4 例位于阴茎干,1 例位于龟头。CT 在 15 例(63%)中检测到阴茎纹理丢失。PSL 仅在播散性疾病的复发或随访中观察到。在那些患有前列腺癌的患者中,PSA 差异很大。15 名(62.5%)死亡,在 PSL 显示后平均 13.3±15.9 个月,其中 9 名患有非前列腺癌恶性肿瘤。PET/CT 发现并描述了部分癌症患者的 PSL,最常见的是前列腺癌患者。PSL 普遍出现在晚期疾病中,并预示着高死亡率,尤其是在非前列腺癌中。